These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37313656)

  • 1. PD1
    Wu C; Duan L; Li H; Liu X; Cai T; Yang Y; Yin Y; Chang W; Zhong L; Zhang L; Cheng Y; Qin H; Wen Z; Wang H; Mai S
    Clin Transl Med; 2023 Jun; 13(6):e1303. PubMed ID: 37313656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
    Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
    Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD1
    Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
    J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
    Qiu Y; Ye W; Wang C; Zang J
    Aging (Albany NY); 2023 Nov; 15(22):13312-13328. PubMed ID: 38015710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
    Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
    J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Natural Killer Cell-related Gene Signature for Improving the Prediction of Prognosis and Immunotherapy Response in Bladder Cancer.
    Ma X; Wei X; Yang G; Li S; Liu R
    Comb Chem High Throughput Screen; 2024; 27(8):1205-1221. PubMed ID: 37653625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
    Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
    Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The m6A Reader YTHDF2 Promotes Bladder Cancer Progression by Suppressing RIG-I-Mediated Immune Response.
    Zhang L; Li Y; Zhou L; Zhou H; Ye L; Ou T; Hong H; Zheng S; Zhou Z; Wu K; Yan Z; Thiery JP; Cui J; Wu S
    Cancer Res; 2023 Jun; 83(11):1834-1850. PubMed ID: 36939388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
    Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis.
    Wang J; Li X; Chen S; Cao J; Fan X; Wang H; Zhang X; Yang L
    Life Sci; 2023 Dec; 335():122253. PubMed ID: 37951536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
    Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G-Protein Subunit Gamma 4 as a Potential Biomarker for Predicting the Response of Chemotherapy and Immunotherapy in Bladder Cancer.
    Duan L; Liu X; Luo Z; Zhang C; Wu C; Mu W; Zuo Z; Pei X; Shao T
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.
    Caramelo B; Zagorac S; Corral S; Marqués M; Real FX
    Eur Urol Oncol; 2023 Aug; 6(4):366-375. PubMed ID: 36890105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8
    Yu A; Hu J; Fu L; Huang G; Deng D; Zhang M; Wang Y; Shu G; Jing L; Li H; Chen X; Yang T; Wei J; Chen Z; Zu X; Luo J
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
    Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
    Front Immunol; 2022; 13():898493. PubMed ID: 35812369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
    Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
    Front Immunol; 2022; 13():964393. PubMed ID: 36211344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
    Zhou R; Zhou J; Muhuitijiang B; Zeng X; Tan W
    Aging (Albany NY); 2023 Jun; 15(12):5355-5380. PubMed ID: 37379131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.